XML 53 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details) - Sales revenue, net - Customer Concentration Risk
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Incyte Corporation (Incyte)      
Concentration Risk [Line Items]      
Percentage of all significant revenue earned 96.00%    
Janssen Biotech, Inc. (Janssen)      
Concentration Risk [Line Items]      
Percentage of all significant revenue earned   85.00% 72.00%
Boehringer Ingelheim GmbH (Boehringer)      
Concentration Risk [Line Items]      
Percentage of all significant revenue earned     12.00%